公开(公告)号：US20240252614A1

公开(公告)日：2024-08-01

申请号：US18413734

申请日：2024-01-16

Applicant: Pfizer Inc.

Inventor： Damon Andrew Hollands Berman ,  Ye Che ,  Alexey Vyacheslavovitch Gribenko ,  Bridget Yih Jiin Huang ,  Weiqiang Li ,  Yan Li ,  Kena Anne Swanson ,  Helen Chen Wang ,  Sabine Susanne Wellnitz ,  Kam Ho Wong ,  Qi Yang ,  Aiping Zhu

IPC: A61K39/155 ,  A61K9/51 ,  A61K39/00 ,  A61K39/12 ,  C07K14/005 ,  C07K16/10

CPC classification number: A61K39/155 ,  A61K9/5123 ,  A61K39/12 ,  C07K14/005 ,  C07K16/10 ,  A61K2039/70

Abstract: The present disclosure relates to hMPV F, PIV3 F and PIV1 F protein mutants, nucleic acids or vectors encoding a hMPV F, PIV3 F and PIV1 F protein mutant, compositions comprising a hMPV F, PIV3 F and PIV1 F protein mutant or nucleic acid, and uses of the hMPV F, PIV3 F and PIV1 F protein mutants, nucleic acids or vectors, and compositions.

公开(公告)号：US20220202923A1

公开(公告)日：2022-06-30

申请号：US17554424

申请日：2021-12-17

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Laurent Oliver Chorro ,  Robert George Konrad Donald ,  Matthew Curtis Griffor ,  Natalie Clare Silmon de Monerri

IPC: A61K39/108 ,  C07K14/245 ,  C07K16/12

Abstract: This disclosure relates to the design of E. coli mutated FimH polypeptides that result in improved biochemical properties and immunogenicity, compositions comprising such polypeptides, and uses thereof.

公开(公告)号：US10703756B2

公开(公告)日：2020-07-07

申请号：US15569874

申请日：2016-04-19

Applicant: Pfizer Inc.

Inventor： Atli Thorarensen ,  Matthew Frank Brown ,  Agustin Casimiro-Garcia ,  Ye Che ,  Mark Edward Flanagan ,  Adam Matthew Gilbert ,  Matthew Merrill Hayward ,  Jean-Baptiste Telliez ,  Rayomand Jal Unwalla ,  John I. Trujillo ,  Sidney Xi Liang

IPC: C07D487/04

Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides, and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

公开(公告)号：US20190270778A1

公开(公告)日：2019-09-05

申请号：US16319985

申请日：2017-07-17

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Yiqing Feng ,  Matthew Merrill Hayward ,  David Hepworth ,  Peter Jones ,  Kaila Neelu ,  Nikolaos Papaioannou

IPC: C07K7/56 ,  A61K38/08 ,  A61P13/12

Abstract: The invention relates to cyclic peptide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to cyclic peptide C5a receptor antagonists of formula (Ia) or formula (Ib), or pharmaceutically acceptable salts thereof, wherein R1a, R1b, R2, R3 and R4 areas defined in the description. C5a receptor antagonists are potentially useful in the treatment of a wide range of 1 disorders, including inflammatory disorders and immune disorders.

公开(公告)号：US20190125861A1

公开(公告)日：2019-05-02

申请号：US16242799

申请日：2019-01-08

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Philip Ralph Dormitzer ,  Alexey Vyacheslavovich Gribenko ,  Luke David Handke ,  Avvari Krishna Prasad ,  Xiayang Qiu ,  Mark Edward Ruppen ,  Xi Song ,  Kena Anne Swanson ,  Srinivas Kodali ,  Xin Xu ,  KariAnn Sweeney Efferen ,  Ping Cai ,  Kristin Rachael Tompkins ,  Lorna del Pilar Nunez

IPC: A61K39/155 ,  C07K14/005 ,  A61K39/12 ,  C12N7/00

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

公开(公告)号：US09180123B2

公开(公告)日：2015-11-10

申请号：US14656123

申请日：2015-03-12

Applicant: Pfizer Inc.

Inventor： Matthew Frank Brown ,  Ye Che ,  Anthony Marfat ,  Michael Joesph Melnick ,  Justin Ian Montgomery ,  Usa Reilly

IPC: C07D401/00 ,  A61K31/4412 ,  A61K31/4439

CPC classification number: A61K31/4412 ,  A61K31/4439 ,  C07D211/86 ,  C07D213/64 ,  C07D401/04 ,  C07D401/08 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/10 ,  C07D409/04 ,  C07D413/10 ,  C07D413/12 ,  C07D417/04 ,  C07D417/10 ,  C07D417/12 ,  Y02A50/473

Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.

Abstract translation: 本发明涉及一类新的异羟肟酸衍生物，它们用作LpxC抑制剂，更具体地说是它们用于治疗细菌感染的用途。

公开(公告)号：US08779148B2

公开(公告)日：2014-07-15

申请号：US14068956

申请日：2013-10-31

Applicant: Pfizer Inc.

Inventor： Usa Reilly ,  Michael Joseph Melnick ,  Matthew Frank Brown ,  Mark Stephen Plummer ,  Justin Ian Montgomery ,  Ye Che ,  Loren Michael Price

IPC: A61K31/44 ,  C07D211/72 ,  C07D413/10 ,  C07D417/12 ,  C07D213/64 ,  C07D405/12 ,  C07D213/69 ,  C07D405/04 ,  C07D401/04 ,  C07D401/10

CPC classification number: C07D405/04 ,  C07D213/64 ,  C07D213/69 ,  C07D401/04 ,  C07D401/10 ,  C07D405/12 ,  C07D413/10 ,  C07D417/12

Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

公开(公告)号：US20140128363A1

公开(公告)日：2014-05-08

申请号：US14154239

申请日：2014-01-14

Applicant: Pfizer Inc.

Inventor： Matthew Frank Brown ,  Ye Che ,  Anthony Marfat ,  Michael Joseph Melnick ,  Justin Ian Montgomery ,  Usa Reilly

IPC: C07D413/10 ,  C07D211/86 ,  C07D401/04 ,  C07D403/04 ,  C07D401/10 ,  C07D401/12

CPC classification number: A61K31/4412 ,  A61K31/4439 ,  C07D211/86 ,  C07D213/64 ,  C07D401/04 ,  C07D401/08 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/10 ,  C07D409/04 ,  C07D413/10 ,  C07D413/12 ,  C07D417/04 ,  C07D417/10 ,  C07D417/12 ,  Y02A50/473

Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.

公开(公告)号：US20240122865A1

公开(公告)日：2024-04-18

申请号：US18275634

申请日：2022-02-15

Applicant: Pfizer Inc.

Inventor： Justin Leigh Bellenger ,  Ye Che ,  Miguel Angel Garcia ,  Lei Hu ,  Mark Carl Noe ,  Shuai Shi

IPC: A61K9/51 ,  A61K9/48 ,  A61K39/12

CPC classification number: A61K9/5123 ,  A61K9/4858 ,  A61K39/12

Abstract: The present disclosure provides methods of protecting ribonucleic acid (RNA) from degradation under certain conditions by contacting the RNA with an amino acid. The present disclosure also provides compositions comprising such amino acid(s) and RNA.

公开(公告)号：US11857622B2

公开(公告)日：2024-01-02

申请号：US17350008

申请日：2021-06-17

Applicant: Pfizer Inc.

Inventor： Yuhang Liu ,  Ye Che ,  Xiaoyuan Sherry Chi ,  Philip Ralph Dormitzer ,  Jennifer Anne Nicki ,  Xiaojie Yao

IPC: A61K39/245 ,  C07K14/045 ,  C12N7/00

CPC classification number: A61K39/245 ,  C07K14/045 ,  C12N7/00 ,  C12N2710/16134

Abstract: The present invention comprises mutants of a wild-type cytomegalovirus (CMV) glycoprotein B (gB) protein that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB), compositions including the mutants and uses thereof. In some embodiments, the mutant is stabilized in a conformation alternative to the gB postfusion conformation.